TokenPost topic
1 TokenPost story is tagged durvalumab. The newest appear first.
Median overall survival was 21.1 months with tarlatamab and durvalumab, compared with 12.7 months with durvalumab alone. The trial tested the combination as maintenance therapy after initial treatment.
Oct 24, 2026, 3:26 PM EDT ยท Business